Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, UK.
Diabetologia. 2011 Jan;54(1):111-9. doi: 10.1007/s00125-010-1916-4. Epub 2010 Sep 29.
AIMS/HYPOTHESIS: Rare mutations in the gene HNF4A, encoding the transcription factor hepatocyte nuclear factor 4α (HNF-4A), account for ~5% of cases of MODY and more frequent variants in this gene may be involved in multifactorial forms of diabetes. Two low-frequency, non-synonymous variants in HNF4A (V255M, minor allele frequency [MAF] ~0.1%; T130I, MAF ~3.0%)-known to influence downstream HNF-4A target gene expression-are of interest, but previous type 2 diabetes association reports were inconclusive. We aimed to evaluate the contribution of these variants to type 2 diabetes susceptibility through large-scale association analysis.
We genotyped both variants in at least 5,745 cases and 14,756 population controls from the UK and Denmark. We also undertook an expanded association analysis that included previously reported and novel genotype data obtained in Danish, Finnish, Canadian and Swedish samples. A meta-analysis incorporating all published association studies of the T130I variant was subsequently carried out in a maximum sample size of 14,279 cases and 26,835 controls.
We found no association between V255M and type 2 diabetes in either the initial (p = 0.28) or the expanded analysis (p = 0.44). However, T130I demonstrated a modest association with type 2 diabetes in the UK and Danish samples (additive per allele OR 1.17 [95% CI 1.08-1.28]; p = 1.5 × 10⁻⁴), which was strengthened in the meta-analysis (OR 1.20 [95% CI 1.10-1.30]; p = 2.1 × 10⁻⁵).
CONCLUSIONS/INTERPRETATION: Our data are consistent with T130I as a low-frequency variant influencing type 2 diabetes risk, but are not conclusive when judged against stringent standards for genome-wide significance. This study exemplifies the difficulties encountered in association testing of low-frequency variants.
目的/假设:编码转录因子肝细胞核因子 4α(HNF-4A)的基因 HNF4A 中的罕见突变占 MODY 的约 5%,而该基因中更常见的变体可能与多种糖尿病形式有关。HNF4A 中的两个低频非同义变体(V255M,次要等位基因频率 [MAF]0.1%;T130I,MAF3.0%)-已知会影响下游 HNF-4A 靶基因表达-引起了人们的关注,但之前关于 2 型糖尿病的关联报告尚无定论。我们旨在通过大规模关联分析评估这些变体对 2 型糖尿病易感性的贡献。
我们在来自英国和丹麦的至少 5745 例病例和 14756 例人群对照中对这两个变体进行了基因分型。我们还进行了扩展的关联分析,其中包括在丹麦、芬兰、加拿大和瑞典样本中获得的先前报道的和新的基因型数据。随后,在最大样本量为 14279 例病例和 26835 例对照的情况下,对 T130I 变体的所有已发表关联研究进行了荟萃分析。
我们在初始分析(p=0.28)或扩展分析(p=0.44)中均未发现 V255M 与 2 型糖尿病之间存在关联。然而,T130I 在英国和丹麦样本中与 2 型糖尿病有适度关联(加性每等位基因 OR 1.17 [95%CI 1.08-1.28];p=1.5×10⁻⁴),在荟萃分析中得到了加强(OR 1.20 [95%CI 1.10-1.30];p=2.1×10⁻⁵)。
结论/解释:我们的数据与 T130I 作为影响 2 型糖尿病风险的低频变体一致,但根据全基因组显著水平的严格标准判断,这些数据并不具有结论性。这项研究说明了在低频变体的关联测试中遇到的困难。